169 related articles for article (PubMed ID: 23994345)
1. Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.
Aliabadi HM; Maranchuk R; Kucharski C; Mahdipoor P; Hugh J; Uludağ H
J Control Release; 2013 Nov; 172(1):219-228. PubMed ID: 23994345
[TBL] [Abstract][Full Text] [Related]
2. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Aliabadi HM; Mahdipoor P; Uludağ H
Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
[TBL] [Abstract][Full Text] [Related]
3. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
[TBL] [Abstract][Full Text] [Related]
4. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
6. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
[TBL] [Abstract][Full Text] [Related]
7. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
8. Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and α-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines.
Plianwong S; Thapa B; Kc RB; Kucharski C; Rojanarata T; Uludağ H
Pharm Res; 2020 Feb; 37(3):46. PubMed ID: 32016611
[TBL] [Abstract][Full Text] [Related]
9. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
10. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
11. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
Parmar MB; Arteaga Ballesteros BE; Fu T; K C RB; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia.
Jafarlou M; Shanehbandi D; Dehghan P; Mansoori B; Othman F; Baradaran B
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1792-1798. PubMed ID: 29113504
[TBL] [Abstract][Full Text] [Related]
13. Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells.
Wu X; Liu X; Sengupta J; Bu Y; Yi F; Wang C; Shi Y; Zhu Y; Jiao Q; Song F
Indian J Exp Biol; 2011 Feb; 49(2):105-12. PubMed ID: 21428211
[TBL] [Abstract][Full Text] [Related]
14. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers.
Li QX; Zhao J; Liu JY; Jia LT; Huang HY; Xu YM; Zhang Y; Zhang R; Wang CJ; Yao LB; Chen SY; Yang AG
Cancer Biol Ther; 2006 Jul; 5(7):860-6. PubMed ID: 16861916
[TBL] [Abstract][Full Text] [Related]
15. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
16. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells.
Dong X; Liu A; Zer C; Feng J; Zhen Z; Yang M; Zhong L
BMC Cancer; 2009 May; 9():133. PubMed ID: 19416503
[TBL] [Abstract][Full Text] [Related]
17. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells.
Navarro G; Sawant RR; Biswas S; Essex S; Tros de Ilarduya C; Torchilin VP
Nanomedicine (Lond); 2012 Jan; 7(1):65-78. PubMed ID: 22191778
[TBL] [Abstract][Full Text] [Related]
19. Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery.
Thapa B; Bahadur Kc R; Uludağ H
Int J Cancer; 2018 Feb; 142(3):597-606. PubMed ID: 28960310
[TBL] [Abstract][Full Text] [Related]
20. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells.
Kang Y; Park MA; Heo SW; Park SY; Kang KW; Park PH; Kim JA
Biochim Biophys Acta; 2013 Mar; 1830(3):2638-48. PubMed ID: 23246576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]